{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:30:54Z","timestamp":1791855054974,"version":"4.3.4"},"reference-count":199,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jad.2025.121081","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T07:39:41Z","timestamp":1767080381000},"page":"121081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A systematic review of ketamine and esketamine-induced long-term potentiation and synaptic scaling: Do the molecular and synaptic plasticity effects inform dosing intervals?"],"prefix":"10.1016","volume":"399","author":[{"given":"Gia Han","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2000-7691","authenticated-orcid":false,"given":"Danica E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6641-0057","authenticated-orcid":false,"given":"Diana","family":"Orsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Chisamore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Di Luch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4773-2191","authenticated-orcid":false,"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jad.2025.121081_bb0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"aan het Rot","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2025.121081_bb0010","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/npp.2016.186","article-title":"Ketamine treatment and global brain connectivity in major depression","volume":"42","author":"Abdallah","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41539-019-0048-y","article-title":"Is plasticity of synapses the mechanism of long-term memory storage?","volume":"4","author":"Abraham","year":"2019","journal-title":"Npj Sci. Learn."},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13041-020-00627-z","article-title":"Ketamine and its metabolite, (2R,6R)-HNK, restore hippocampal LTP and long-term spatial memory in the Wistar-Kyoto rat model of depression","volume":"13","author":"Aleksandrova","year":"2020","journal-title":"Mol. Brain"},{"key":"10.1016\/j.jad.2025.121081_bb0025","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6619515","article-title":"Role of BDNF-mTORC1 signaling pathway in female depression","volume":"2021","author":"An","year":"2021","journal-title":"Neural Plast."},{"key":"10.1016\/j.jad.2025.121081_bb0030","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jad.2018.02.056","article-title":"Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial","volume":"235","author":"Arabzadeh","year":"2018","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.jad.2025.121081_bb0035","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mp.2017.16","article-title":"The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment","volume":"22","author":"Ashok","year":"2017","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0040","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.biopsych.2009.02.007","article-title":"Gender-specific impact of brain-derived neurotrophic factor signaling on stress-induced depression-like behavior","volume":"66","author":"Autry","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"7354","key":"10.1016\/j.jad.2025.121081_bb0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.jad.2025.121081_bb0050","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/ijnp\/pyab023","article-title":"Ketamine for bipolar depression: a systematic review","volume":"24","author":"Bahji","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2025.121081_bb0055","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"278","author":"Bahji","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.121081_bb0060","series-title":"Major Depressive Disorder","author":"Bains","year":"2025"},{"issue":"12","key":"10.1016\/j.jad.2025.121081_bb0065","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.biopsych.2014.04.014","article-title":"Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity","volume":"76","author":"Belujon","year":"2014","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2025.121081_bb0070","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2025.121081_bb0075","first-page":"598","article-title":"Dissecting the components of long-term potentiation","volume":"14","author":"Blundon","year":"2008","journal-title":"Neurosci. Rev. J. Bringing Neurobiol. Neurol. Psychiatry."},{"issue":"8","key":"10.1016\/j.jad.2025.121081_bb0080","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1177\/02698811231189432","article-title":"Ketamine-induced changes in resting state connectivity, 2h after the drug administration in patients with remitted depression","volume":"37","author":"Burrows","year":"2023","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.jad.2025.121081_bb0085","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neulet.2018.07.038","article-title":"PET imaging of synaptic density: a new tool for investigation of neuropsychiatric diseases","volume":"691","author":"Cai","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jad.2025.121081_bb0090","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jad.2024.04.039","article-title":"Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: a systematic review and meta-analysis","volume":"356","author":"Calder","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.jad.2025.121081_bb0095","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.cub.2009.01.037","article-title":"Functional MRI evidence for LTP-induced neural network reorganization","volume":"19","author":"Canals","year":"2009","journal-title":"Curr. Biol."},{"issue":"7","key":"10.1016\/j.jad.2025.121081_bb0100","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","volume":"175","author":"Canuso","year":"2018","journal-title":"Am. J. Psychiatry."},{"issue":"3","key":"10.1016\/j.jad.2025.121081_bb0105","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1124\/pr.117.014977","article-title":"International union of basic and clinical pharmacology CIV: the neurobiology of treatment-resistant depression: from antidepressant classifications to novel pharmacological targets","volume":"70","author":"Caraci","year":"2018","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.jad.2025.121081_bb0110","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a005728","article-title":"Presynaptic LTP and LTD of excitatory and inhibitory synapses","volume":"4","author":"Castillo","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1\u20132","key":"10.1016\/j.jad.2025.121081_bb0115","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/jnr.23863","article-title":"Sex differences in brain-derived neurotrophic factor signaling and functions","volume":"95","author":"Chan","year":"2017","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jad.2025.121081_bb0120","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jad.2017.09.008","article-title":"Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: a randomized control study","volume":"225","author":"Chen","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.121081_bb0125","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jpsychires.2021.11.006","article-title":"Is one or two infusions better in the first week of low-dose ketamine treatment for medication-resistant depression? A post hoc pooled analysis of randomized placebo-controlled and open-label trials","volume":"144","author":"Chen","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2025.121081_bb0130","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/NDT.S391096","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray plus a newly initiated oral antidepressant in adult patients with treatment-resistant depression: a randomized, double-blind, multicenter, active-controlled study conducted in China and USA","volume":"19","author":"Chen","year":"2023","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"6709","key":"10.1016\/j.jad.2025.121081_bb0135","doi-asserted-by":"crossref","DOI":"10.1126\/science.ado7010","article-title":"Brain region\u2013specific action of ketamine as a rapid antidepressant","volume":"385","author":"Chen","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jad.2025.121081_bb0140","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jad.2025.04.119","article-title":"The effects of ketamine and esketamine on measures of quality of life in major depressive disorder and treatment-resistant depression: a systematic review","volume":"382","author":"Cheng","year":"2025","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.121081_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.116282","article-title":"Effect of intravenous ketamine on suicidality in adults with treatment-resistant depression: a real world effectiveness study","volume":"343","author":"Chen-Li","year":"2025","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2025.121081_bb0150","author":"Clinical investigation of medicinal products in the treatment of depression - Scientific guideline"},{"key":"10.1016\/j.jad.2025.121081_bb0155","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jpsychires.2024.03.002","article-title":"Oral prolonged-release ketamine in treatment-resistant depression - a double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation \u2013 clinical and safety results","volume":"173","author":"Colla","year":"2024","journal-title":"J. Psychiatr. Res."},{"issue":"7","key":"10.1016\/j.jad.2025.121081_bb0160","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1021\/acschemneuro.8b00698","article-title":"Delayed antidepressant efficacy and the desensitization hypothesis","volume":"10","author":"Commons","year":"2019","journal-title":"ACS Chem. Nerosci."},{"issue":"7","key":"10.1016\/j.jad.2025.121081_bb0165","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.biopsych.2012.03.029","article-title":"Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression","volume":"72","author":"Cornwell","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.121081_bb0170","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jad.2019.11.086","article-title":"Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study","volume":"264","author":"Correia-Melo","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.121081_bb0175","author":"Covidence"},{"issue":"2","key":"10.1016\/j.jad.2025.121081_bb0180","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2025.121081_bb0185","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"10.1016\/j.jad.2025.121081_bb0190","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2025.121081_bb0195","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.euroneuro.2023.02.010","article-title":"Rethinking ketamine and esketamine action: are they antidepressants with mood-stabilizing properties?","volume":"70","author":"d\u2019Andrea","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2025.121081_bb0200","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jad.2023.12.038","article-title":"The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: a post-hoc analysis of pooled real-world data","volume":"348","author":"d\u2019Andrea","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.121081_bb0205","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12991-023-00440-7","article-title":"The economic and humanistic burden of bipolar disorder in adults in the United States","volume":"22","author":"Dembek","year":"2023","journal-title":"Ann. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2025.121081_bb0210","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1101\/lm.6.3.284","article-title":"BDNF regulates the intrinsic excitability of cortical neurons","volume":"6","author":"Desai","year":"1999","journal-title":"Learn. Mem."},{"issue":"12","key":"10.1016\/j.jad.2025.121081_bb0215","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4088\/JCP.09m05327blu","article-title":"Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder","volume":"71","author":"DiazGranados","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"8","key":"10.1016\/j.jad.2025.121081_bb0220","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"issue":"8","key":"10.1016\/j.jad.2025.121081_bb0225","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0230","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1192\/bjp.2018.196","article-title":"Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"214","author":"Domany","year":"2019","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2025.121081_bb0235","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1017\/S1461145712000545","article-title":"Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder","volume":"16","author":"Duncan","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0240","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.brainresbull.2005.11.003","article-title":"A direct demonstration of cortical LTP in humans: a combined TMS\/EEG study","volume":"69","author":"Esser","year":"2006","journal-title":"Brain Res. Bull."},{"issue":"9","key":"10.1016\/j.jad.2025.121081_bb0245","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/s41386-018-0057-1","article-title":"7T 1H-MRS in major depressive disorder: a Ketamine Treatment Study","volume":"43","author":"Evans","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2025.121081_bb0250","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231202723","article-title":"Ketamine for bipolar depression: an updated systematic review","volume":"13","author":"Fancy","year":"2023","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.jad.2025.121081_bb0255","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/bdi.13284","article-title":"Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression","volume":"25","author":"Fancy","year":"2023","journal-title":"Bipolar Disord."},{"issue":"7","key":"10.1016\/j.jad.2025.121081_bb0260","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","volume":"25","author":"Fava","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"10","key":"10.1016\/j.jad.2025.121081_bb0265","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"30","key":"10.1016\/j.jad.2025.121081_bb0270","doi-asserted-by":"crossref","first-page":"8031","DOI":"10.1523\/JNEUROSCI.2003-07.2007","article-title":"Evidence that long-term potentiation occurs within individual hippocampal synapses during learning","volume":"27","author":"Fedulov","year":"2007","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.jad.2025.121081_bb0275","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1176\/appi.ajp.20240515","article-title":"Esketamine treatment for depression in adults: a PRISMA systematic review and meta-analysis","volume":"182","author":"Fountoulakis","year":"2025","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2025.121081_bb0280","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m13191","article-title":"Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I)","volume":"81","author":"Fu","year":"2020","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0285","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3949\/ccjm.75.1.57","article-title":"The STAR*D study: treating depression in the real world","volume":"75","author":"Gaynes","year":"2008","journal-title":"Cleve. Clin. J. Med."},{"issue":"10440","key":"10.1016\/j.jad.2025.121081_bb0290","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet Lond Engl."},{"issue":"4","key":"10.1016\/j.jad.2025.121081_bb0295","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","year":"2024","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0300","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1176\/appi.ajp.161.1.163","article-title":"Antidepressant treatment in bipolar versus unipolar depression","volume":"161","author":"Ghaemi","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2025.121081_bb0305","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/sj.mp.4001793","article-title":"Treatment-resistant bipolar disorder","volume":"11","author":"Gitlin","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2025.121081_bb0310","first-page":"11","article-title":"Approaches and limitations in the investigation of synaptic transmission and plasticity","author":"Glasgow","year":"2019","journal-title":"Front. Synaptic. Neurosci."},{"issue":"7","key":"10.1016\/j.jad.2025.121081_bb0315","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1038\/s41591-024-03063-x","article-title":"Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial","volume":"30","author":"Glue","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jad.2025.121081_bb0320","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.brainres.2015.03.019","article-title":"Effect of acute NR2B antagonist treatment on long-term potentiation in the rat hippocampus","volume":"1609","author":"Graef","year":"2015","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.jad.2025.121081_bb0325","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bdi.12487","article-title":"Ketamine versus midazolam in bipolar depression with suicidal thoughts: a pilot midazolam-controlled randomized clinical trial","volume":"19","author":"Grunebaum","year":"2017","journal-title":"Bipolar Disord."},{"issue":"4","key":"10.1016\/j.jad.2025.121081_bb0330","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1176\/appi.ajp.2017.17060647","article-title":"Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial","volume":"175","author":"Grunebaum","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.121081_bb0335","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3204519","article-title":"Amyloid-\u03b2-induced dysregulation of AMPA receptor trafficking","volume":"2016","author":"Guntupalli","year":"2016","journal-title":"Neural Plast."},{"issue":"2","key":"10.1016\/j.jad.2025.121081_bb0340","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1017\/S1461145713001119","article-title":"Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression","volume":"17","author":"Haile","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"9","key":"10.1016\/j.jad.2025.121081_bb0345","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1523\/JNEUROSCI.1843-17.2017","article-title":"A unique homeostatic signaling pathway links synaptic inactivity to postsynaptic mTORC1","volume":"38","author":"Henry","year":"2018","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0350","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1192\/bjp.2018.257","article-title":"Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition","volume":"214","author":"Hidalgo-Mazzei","year":"2019","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"issue":"2","key":"10.1016\/j.jad.2025.121081_bb0355","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.tins.2009.11.003","article-title":"mTOR signaling: at the crossroads of plasticity, memory, and disease","volume":"33","author":"Hoeffer","year":"2010","journal-title":"Trends Neurosci."},{"issue":"12","key":"10.1016\/j.jad.2025.121081_bb0360","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.biopsych.2022.10.018","article-title":"Differences in quantification of the metabotropic glutamate receptor 5 (mGluR5) across bipolar disorder and major depressive disorder","volume":"93","author":"Holmes","year":"2023","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0365","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.jad.2025.121081_bb0370","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/NDT.S396424","article-title":"Cognitive impairment mechanism in patients with bipolar disorder","volume":"19","author":"Huang","year":"2023","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"6","key":"10.1016\/j.jad.2025.121081_bb0375","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/npp.2011.338","article-title":"Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study","volume":"37","author":"Ibrahim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2025.121081_bb0380","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2147\/NDT.S246294","article-title":"Prevalence of comorbid anxiety disorders and their associated factors in patients with bipolar disorder or major depressive disorder","volume":"16","author":"Inoue","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"6","key":"10.1016\/j.jad.2025.121081_bb0385","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/brainsci13060909","article-title":"The role of ketamine in the treatment of bipolar depression: a scoping review","volume":"13","author":"Jawad","year":"2023","journal-title":"Brain Sci."},{"issue":"10","key":"10.1016\/j.jad.2025.121081_bb0390","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3390\/ph15101203","article-title":"Monoamine neurotransmitters control basic emotions and affect major depressive disorders","volume":"15","author":"Jiang","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"10","key":"10.1016\/j.jad.2025.121081_bb0395","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/mp.2011.46","article-title":"New medications for drug addiction hiding in glutamatergic neuroplasticity","volume":"16","author":"Kalivas","year":"2011","journal-title":"Mol. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2025.121081_bb0400","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.neuron.2020.05.015","article-title":"Targeting homeostatic synaptic plasticity for treatment of mood disorders","volume":"106","author":"Kavalali","year":"2020","journal-title":"Neuron"},{"issue":"10","key":"10.1016\/j.jad.2025.121081_bb0405","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3390\/biomedicines12102283","article-title":"Ketamine, esketamine, and arketamine: their mechanisms of action and applications in the treatment of depression and alleviation of depressive symptoms","volume":"12","author":"Kawczak","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-023-02451-0","article-title":"Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression","volume":"13","author":"Kopelman","year":"2023","journal-title":"Transl. Psychiatry"},{"issue":"8","key":"10.1016\/j.jad.2025.121081_bb0415","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0006-3223(02)01787-0","article-title":"Comorbidity and depression treatment","volume":"53","author":"Krishnan","year":"2003","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0420","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41386-023-01629-w","article-title":"Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms","volume":"49","author":"Krystal","year":"2024","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.jad.2025.121081_bb0425","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.121081_bb0430","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jad.2024.03.165","article-title":"Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: a systematic review","volume":"355","author":"Le","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.121081_bb0435","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jad.2017.11.003","article-title":"Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: a systematic review","volume":"227","author":"Lee","year":"2018","journal-title":"J. Affect. Disord."},{"issue":"5994","key":"10.1016\/j.jad.2025.121081_bb0440","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jad.2025.121081_bb0445","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/hbm.23085","article-title":"The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study","volume":"37","author":"Li","year":"2016","journal-title":"Hum. Brain Mapp."},{"issue":"7","key":"10.1016\/j.jad.2025.121081_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109513","article-title":"A synaptic locus for TrkB signaling underlying ketamine rapid antidepressant action","volume":"36","author":"Lin","year":"2021","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0455","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m13964","article-title":"Epidemiology of treatment-resistant depression in the United States","volume":"83","author":"Liu","year":"2021","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0460","first-page":"7","article-title":"Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?","volume":"7","author":"Ma","year":"2020","journal-title":"Mil. Med. Res."},{"issue":"3","key":"10.1016\/j.jad.2025.121081_bb0465","first-page":"269","article-title":"The clinical characterization of the adult patient with depression aimed at personalization of management","volume":"19","author":"Maj","year":"2020","journal-title":"World Psychiatry Off. J. World Psychiatr Assoc. WPA."},{"key":"10.1016\/j.jad.2025.121081_bb0470","article-title":"Biological correlates of treatment resistant depression: a review of peripheral biomarkers","volume":"14","author":"Mancuso","year":"2023","journal-title":"Front. Psych."},{"key":"10.1016\/j.jad.2025.121081_bb0475","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.jad.2025.121081_bb0480","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/bdi.13296","article-title":"Treating bipolar depression with esketamine: safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression","volume":"25","author":"Martinotti","year":"2023","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2025.121081_bb0485","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jad.2021.12.097","article-title":"A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings","volume":"301","author":"McInnes","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"11","key":"10.1016\/j.jad.2025.121081_bb0490","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1080\/03007995.2019.1636017","article-title":"Bipolar depression: the clinical characteristics and unmet needs of a complex disorder","volume":"35","author":"McIntyre","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"issue":"11","key":"10.1016\/j.jad.2025.121081_bb0495","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40263-024-01114-y","article-title":"Glutamatergic modulators for major depression from theory to clinical use","volume":"38","author":"McIntyre","year":"2024","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.jad.2025.121081_bb0500","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/da.22063","article-title":"Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions","volume":"30","author":"McIntyre","year":"2013","journal-title":"Depress. Anxiety"},{"issue":"10265","key":"10.1016\/j.jad.2025.121081_bb0505","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(20)31544-0","article-title":"Bipolar disorders","volume":"396","author":"McIntyre","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2025.121081_bb0510","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jad.2020.07.045","article-title":"Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: economic burden and healthcare resource utilization","volume":"277","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.121081_bb0515","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jad.2020.05.088","article-title":"The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: results from the Canadian Rapid Treatment Center of Excellence","volume":"274","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.jad.2025.121081_bb0520","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2025.121081_bb0525","first-page":"394","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry Off. J. World Psychiatr Assoc. WPA."},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0530","doi-asserted-by":"crossref","DOI":"10.1017\/S1092852924002451","article-title":"Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial","volume":"30","author":"McIntyre","year":"2025","journal-title":"CNS Spectr."},{"issue":"8","key":"10.1016\/j.jad.2025.121081_bb0535","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13211","article-title":"Assessment of relationship of ketamine dose with magnetic resonance spectroscopy of Glx and GABA responses in adults with major depression: a randomized clinical trial","volume":"3","author":"Milak","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"8","key":"10.1016\/j.jad.2025.121081_bb0540","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J. Neurosci."},{"issue":"10","key":"10.1016\/j.jad.2025.121081_bb0545","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2025.121081_bb0550","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2025.121081_bb0555","doi-asserted-by":"crossref","first-page":"e509","DOI":"10.1038\/tp.2015.10","article-title":"Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder","volume":"5","author":"Murrough","year":"2015","journal-title":"Transl. Psychiatry"},{"issue":"Suppl. 8","key":"10.1016\/j.jad.2025.121081_bb0560","first-page":"17","article-title":"Prevalence and management of treatment-resistant depression","volume":"68","author":"Nemeroff","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2025.121081_bb0565","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.neuron.2016.12.015","article-title":"A brief history of long-term potentiation","volume":"93","author":"Nicoll","year":"2017","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0570","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40345-023-00308-5","article-title":"NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial","volume":"11","author":"Nierenberg","year":"2023","journal-title":"Int. J. Bipolar Disord."},{"issue":"7","key":"10.1016\/j.jad.2025.121081_bb0575","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/ijnp\/pyaa027","article-title":"Managing esketamine treatment frequency toward successful outcomes: analysis of phase 3 data","volume":"23","author":"Nijs","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2025.121081_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102127","article-title":"Ketamine for the treatment of major depression: a systematic review and meta-analysis","volume":"62","author":"Nikolin","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"16","key":"10.1016\/j.jad.2025.121081_bb0585","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1523\/JNEUROSCI.4998-12.2013","article-title":"Acute suppression of spontaneous neurotransmission drives synaptic potentiation","volume":"33","author":"Nosyreva","year":"2013","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.jad.2025.121081_bb0590","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/bdi.12118","article-title":"Neural correlates of rapid antidepressant response to ketamine in bipolar disorder","volume":"16","author":"Nugent","year":"2014","journal-title":"Bipolar Disord."},{"issue":"2","key":"10.1016\/j.jad.2025.121081_bb0595","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression\u2014TRANSFORM-3","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"12","key":"10.1016\/j.jad.2025.121081_bb0600","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/pcn.13734","article-title":"Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial","volume":"78","author":"Ohtani","year":"2024","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2025.121081_bb0605","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0610","doi-asserted-by":"crossref","first-page":"109","DOI":"10.31887\/DCNS.2013.15.1\/dpark","article-title":"The aging mind: neuroplasticity in response to cognitive training","volume":"15","author":"Park","year":"2013","journal-title":"Dialogues Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0615","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1186\/s12888-024-05951-5","article-title":"A randomized controlled pilot study of daily intravenous ketamine over three days for treatment-resistant depression","volume":"24","author":"Pattanaseri","year":"2024","journal-title":"BMC Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2025.121081_bb0620","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1007\/s00213-021-05939-z","article-title":"Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression","volume":"238","author":"Pennybaker","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jad.2025.121081_bb0625","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jad.2021.08.036","article-title":"Economic impact of treatment-resistant depression: a retrospective observational study","volume":"295","author":"P\u00e9rez-Sola","year":"2021","journal-title":"J. Affect. Disord."},{"issue":"7","key":"10.1016\/j.jad.2025.121081_bb0630","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1523\/JNEUROSCI.21-07-02308.2001","article-title":"LTD induction in adult visual cortex: role of stimulus timing and inhibition","volume":"21","author":"Perrett","year":"2001","journal-title":"J. Neurosci."},{"issue":"7","key":"10.1016\/j.jad.2025.121081_bb0635","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.euroneuro.2019.06.001","article-title":"Patterns of response to antidepressants in major depressive disorder: Drug resistance or worsening of depression are associated with a bipolar diathesis","volume":"29","author":"Perugi","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.jad.2025.121081_bb0640","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","article-title":"Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial","volume":"176","author":"Phillips","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2025.121081_bb0645","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","article-title":"Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial","volume":"176","author":"Phillips","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2025.121081_bb0650","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41386-019-0570-x","article-title":"Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression","volume":"45","author":"Phillips","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.jad.2025.121081_bb0655","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41386-019-0570-x","article-title":"Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression","volume":"45","author":"Phillips","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.jad.2025.121081_bb0660","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/s41386-024-01895-2","article-title":"Ketamine induced synaptic plasticity operates independently of long-term potentiation","volume":"49","author":"Piazza","year":"2024","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.jad.2025.121081_bb0665","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2025.121081_bb0670","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.biopsych.2009.04.029","article-title":"Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression","volume":"66","author":"Price","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2025.121081_bb0675","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3892\/etm.2021.10565","article-title":"Neuroplasticity and depression: rewiring the brain\u2019s networks through pharmacological therapy (Review)","volume":"22","author":"R\u0103dulescu","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.jad.2025.121081_bb0680","doi-asserted-by":"crossref","DOI":"10.1177\/2470547019861417","article-title":"Neurophysiological effect of ketamine on prefrontal cortex in treatment-resistant depression: a combined transcranial magnetic stimulation\u2013electroencephalography study","volume":"3","author":"Ramakrishnan","year":"2019","journal-title":"Chronic Stress"},{"issue":"5","key":"10.1016\/j.jad.2025.121081_bb0685","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/0269881113478283","article-title":"Serial infusions of low-dose ketamine for major depression","volume":"27","author":"Rasmussen","year":"2013","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.jad.2025.121081_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynstr.2021.100422","article-title":"Low-dose S-ketamine exerts antidepressant-like effects via enhanced hippocampal synaptic plasticity in postpartum depression rats","volume":"16","author":"Ren","year":"2022","journal-title":"Neurobiol. Stress"},{"key":"10.1016\/j.jad.2025.121081_bb0695","author":"Research C for DE and. Major Depressive Disorder"},{"key":"10.1016\/j.jad.2025.121081_bb0700","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brainres.2014.03.004","article-title":"Clinically relevant concentrations of ketamine mainly affect long-term potentiation rather than basal excitatory synaptic transmission and do not change paired-pulse facilitation in mouse hippocampal slices","volume":"1560","author":"Ribeiro","year":"2014","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.jad.2025.121081_bb0705","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/ijerph15040771","article-title":"Predictors of response to ketamine in treatment resistant major depressive disorder and bipolar disorder","volume":"15","author":"Rong","year":"2018","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"11","key":"10.1016\/j.jad.2025.121081_bb0710","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2025.121081_bb0715","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13651501.2017.1297834","article-title":"Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression","volume":"21","author":"Rybakowski","year":"2017","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"13","key":"10.1016\/j.jad.2025.121081_bb0720","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1017\/S0033291720004560","article-title":"Modulation of the functional connectome in major depressive disorder by ketamine therapy","volume":"52","author":"Sahib","year":"2022","journal-title":"Psychol. Med."},{"issue":"4","key":"10.1016\/j.jad.2025.121081_bb0725","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.biopsych.2008.08.014","article-title":"Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine","volume":"65","author":"Salvadore","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.jad.2025.121081_bb0730","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/npp.2010.24","article-title":"Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine","volume":"35","author":"Salvadore","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.jad.2025.121081_bb0735","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1017\/S1461145711001593","article-title":"An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression","volume":"15","author":"Salvadore","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.jad.2025.121081_bb0740","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.yfrne.2006.09.004","article-title":"Estrogen and brain-derived neurotrophic factor (BDNF) in hippocampus: complexity of steroid hormone-growth factor interactions in the adult CNS","volume":"27","author":"Scharfman","year":"2006","journal-title":"Front. Neuroendocrinol."},{"issue":"13","key":"10.1016\/j.jad.2025.121081_bb0745","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1523\/JNEUROSCI.19-13-05683.1999","article-title":"Direct evidence for biphasic cAMP responsive element-binding protein phosphorylation during long-term potentiation in the rat dentate gyrus in vivo","volume":"19","author":"Schulz","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jad.2025.121081_bb0750","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jad.2024.03.137","article-title":"Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: a systematic review and meta-analysis","volume":"356","author":"Seshadri","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.121081_bb0755","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41398-020-00897-0","article-title":"A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression","volume":"10","author":"Shiroma","year":"2020","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0760","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bdi.12026","article-title":"Evidence-based treatment strategies for treatment-resistant bipolar depression: a systematic review","volume":"15","author":"Sienaert","year":"2013","journal-title":"Bipolar Disord."},{"issue":"8","key":"10.1016\/j.jad.2025.121081_bb0765","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2025.121081_bb0770","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2025.121081_bb0775","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14548","article-title":"Comparative effectiveness of intravenous ketamine and intranasal esketamine in clinical practice among patients with treatment-refractory depression: an observational study","volume":"84","author":"Singh","year":"2023","journal-title":"J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2025.121081_bb0780","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S2215-0366(22)00317-0","article-title":"Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability","volume":"9","author":"Smith-Apeldoorn","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"24","key":"10.1016\/j.jad.2025.121081_bb0785","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.3390\/ijms20246193","article-title":"Synaptic plasticity shapes brain connectivity: implications for network topology","volume":"20","author":"Stampanoni Bassi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.jad.2025.121081_bb0790","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1176\/appi.ps.55.2.117","article-title":"Economic grand rounds: the economic burden of bipolar disorder","volume":"55","author":"Stimmel","year":"2004","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.jad.2025.121081_bb0795","author":"Study Quality Assessment Tools"},{"issue":"13","key":"10.1016\/j.jad.2025.121081_bb0800","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/npp.2017.94","article-title":"Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression","volume":"42","author":"Su","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.jad.2025.121081_bb0805","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/ijnp\/pyad014","article-title":"A randomized, double-blind, midazolam-controlled trial of low-dose ketamine infusion in patients with treatment-resistant depression and prominent suicidal ideation","volume":"26","author":"Su","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.jad.2025.121081_bb0810","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/ijnp\/pyad014","article-title":"A randomized, double-blind, midazolam-controlled trial of low-dose ketamine infusion in patients with treatment-resistant depression and prominent suicidal ideation","volume":"26","author":"Su","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2025.121081_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2025.116377","article-title":"Low-dose ketamine improved brain network integrity among patients with treatment-resistant depression and suicidal ideation","volume":"345","author":"Su","year":"2025","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0820","first-page":"45","article-title":"Ketamine enhances visual sensory evoked potential long-term potentiation in patients with major depressive disorder","volume":"5","author":"Sumner","year":"2020","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging."},{"issue":"7","key":"10.1016\/j.jad.2025.121081_bb0825","article-title":"Economic burden of treatment-resistant depression on the U.S. health care system","volume":"25","author":"Sussman","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0830","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12888-021-03538-y","article-title":"Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study","volume":"21","author":"Takahashi","year":"2021","journal-title":"BMC Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2025.121081_bb0835","first-page":"396","article-title":"A comparison between single and double-dose intravenous ketamine administration in bipolar mood disorder: a double-blind controlled clinical trial","volume":"18","author":"Talaei","year":"2023","journal-title":"Iran. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0840","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12974-020-01843-z","article-title":"Extrasynaptic CaMKII\u03b1 is involved in the antidepressant effects of ketamine by downregulating GluN2B receptors in an LPS-induced depression model","volume":"17","author":"Tang","year":"2020","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0845","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4103\/0253-7176.96161","article-title":"Rapid antidepressant response with ketamine: is it the solution to resistant depression?","volume":"34","author":"Thakurta","year":"2012","journal-title":"Indian J. Psychol. Med."},{"issue":"617","key":"10.1016\/j.jad.2025.121081_bb0850","doi-asserted-by":"crossref","first-page":"e852","DOI":"10.3399\/bjgp13X675430","article-title":"Prevalence of treatment-resistant depression in primary care: cross-sectional data","volume":"63","author":"Thomas","year":"2013","journal-title":"Br. J. Gen. Pract. J. R. Coll. Gen. Pract."},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0855","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-020-0844-4","article-title":"A randomized placebo-controlled PET study of ketamine\u2019s effect on serotonin1B receptor binding in patients with SSRI-resistant depression","volume":"10","author":"Tiger","year":"2020","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2025.121081_bb0860","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cell.2008.10.008","article-title":"The self-tuning neuron: synaptic scaling of excitatory synapses","volume":"135","author":"Turrigiano","year":"2008","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jad.2025.121081_bb0865","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cell.2008.10.008","article-title":"The self-tuning neuron: synaptic scaling of excitatory synapses","volume":"135","author":"Turrigiano","year":"2008","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0870","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a005736","article-title":"Homeostatic synaptic plasticity: local and global mechanisms for stabilizing neuronal function","volume":"4","author":"Turrigiano","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"2","key":"10.1016\/j.jad.2025.121081_bb0875","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pscychresns.2010.10.009","article-title":"The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS","volume":"191","author":"Valentine","year":"2011","journal-title":"Psychiatry Res. Neuroimaging"},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0880","first-page":"21","article-title":"Comparison of antidepressant responses in patients with bipolar vs. unipolar depression: a meta-analytic review","volume":"44","author":"V\u00e1zquez","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jad.2025.121081_bb0885","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.euroneuro.2024.12.013","article-title":"Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: findings from a 32-week randomised, open-label, rater-blinded phase IIIb study","volume":"93","author":"Vieta","year":"2025","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.jad.2025.121081_bb0890","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, Open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.121081_bb0895","article-title":"Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial","volume":"385","author":"Wang","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2025.121081_bb0900","first-page":"10","article-title":"Intravascular ketamine increases theta-burst but not high frequency tetanus induced LTP at CA3-CA1 synapses within three hours and devoid of an increase in spine density","author":"Widman","year":"2018","journal-title":"Front. Synaptic. Neurosci."},{"key":"10.1016\/j.jad.2025.121081_bb0905","first-page":"14","article-title":"Short-term ketamine use in bipolar depression: a review of the evidence for short-term treatment management","author":"Wilkowska","year":"2023","journal-title":"Front. Psychiatry."},{"key":"10.1016\/j.jad.2025.121081_bb0910","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2147\/NDT.S325000","article-title":"Intravenous ketamine infusions in treatment-resistant bipolar depression: an open-label naturalistic observational study","volume":"17","author":"Wilkowska","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"4","key":"10.1016\/j.jad.2025.121081_bb0915","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bdi.13409","article-title":"Anhedonia in bipolar depression treated with ketamine","volume":"26","author":"Wilkowska","year":"2024","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2025.121081_bb0920","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jad.2024.01.142","article-title":"A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): a systematic review","volume":"350","author":"Wong","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"11","key":"10.1016\/j.jad.2025.121081_bb0925","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cub.2021.03.024","article-title":"Homeostatic synaptic scaling establishes the specificity of an associative memory","volume":"31","author":"Wu","year":"2021","journal-title":"Curr. Biol."},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0930","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-025-03310-w","article-title":"The characteristics of anhedonia in depression: a review from a clinically oriented perspective","volume":"15","author":"Wu","year":"2025","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2025.121081_bb0935","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2147\/NDT.S245166","article-title":"Pharmacological treatment of bipolar depression: what are the current and emerging options?","volume":"16","author":"Yalin","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2025.121081_bb0940","first-page":"12","article-title":"Effect of ketamine on LTP and NMDAR EPSC in hippocampus of the chronic social defeat stress mice model of depression","author":"Yang","year":"2018","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.jad.2025.121081_bb0945","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2023.1192544","article-title":"Differentiation between bipolar disorder and major depressive disorder in adolescents: from clinical to biological biomarkers","volume":"17","author":"Yang","year":"2023","journal-title":"Front. Hum. Neurosci."},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0950","first-page":"21","article-title":"Sex differences and the HPA axis: implications for psychiatric disease","volume":"1","author":"Young","year":"1998","journal-title":"J. Gend. Specif. Med."},{"issue":"7604","key":"10.1016\/j.jad.2025.121081_bb0955","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jad.2025.121081_bb0960","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1523\/JNEUROSCI.1316-22.2022","article-title":"NMDA receptor activation-dependent antidepressant-relevant behavioral and synaptic actions of ketamine","volume":"43","author":"Zanos","year":"2023","journal-title":"J. Neurosci."},{"issue":"8","key":"10.1016\/j.jad.2025.121081_bb0965","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2025.121081_bb0970","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.121081_bb0975","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.86022","article-title":"Ketamine\u2019s rapid antidepressant effects are mediated by Ca2+\u2212permeable AMPA receptors. Scharfman HE, Chen L, Lee HK, eds","volume":"12","author":"Zaytseva","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.jad.2025.121081_bb0980","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109219","article-title":"Arketamine, a new rapid-acting antidepressant: a historical review and future directions","volume":"218","author":"Zhang","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2025.121081_bb0985","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.09.013","article-title":"Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression","volume":"106","author":"Zheng","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2025.121081_bb0990","first-page":"10","article-title":"Co-morbidity of dsm-iv personality disorder in major depressive disorder among psychiatric outpatients in china: a further analysis of an epidemiologic survey in a clinical population","author":"Zheng","year":"2019","journal-title":"Front. Psychiatry."},{"issue":"1","key":"10.1016\/j.jad.2025.121081_bb0995","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12888-024-05716-0","article-title":"Rapid and sustained antidepressant effects of intravenous ketamine in treatment-resistant major depressive disorder and suicidal ideation: a randomized clinical trial","volume":"24","author":"Zolghadriha","year":"2024","journal-title":"BMC Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725025236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725025236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T04:10:26Z","timestamp":1776571826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725025236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":199,"alternative-id":["S0165032725025236"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.121081","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of ketamine and esketamine-induced long-term potentiation and synaptic scaling: Do the molecular and synaptic plasticity effects inform dosing intervals?","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.121081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"121081"}}